The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of Bydureon (exenatide extended-release for injectable suspension; Amylin) outweigh the potential risks including medullary thyroid carcinoma (MTC) and acute pancreatitis.
